JPRN-UMIN000037158已完成未知
Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetes - Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetes
Minami Osaka hospital0 个研究点目标入组 24 人开始时间: 2019年6月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who have a history of severe ketosis, diabetic coma or pre-coma within 6 weeks of study start. 2.Patients who developed severe hypoglycemia (diabetic coma or pre-coma, convulsions, etc. require assistance by a third party) within 6 weeks of study start. 3.Patients who have a history of medically important renal diseases such as renal vascular occlusive disease, nephrectomy and renal transplantation. 4.Patients who show symptoms of dysuria, anuria, oliguria or urinary retention 5.Patients who developed urinary tract infections and genital infections with subjective symptoms within 6 weeks of the study start. 6. Patients with proliferative retinopathy (however, patients with photocoagulation etc. who have stable symptoms can be included). 7. Patients with severe gastrointestinal disorders within 2 weeks of the study, or patients with a history of severe gastrointestinal disorders. 8.Patients with acute coronary syndrome, cerebrovascular disorder within 3 months. 9. Women and lactating patients who may or may be pregnant. 10. Patients with severe infections, before and after surgery, with serious trauma. 11. Patients receiving systemic administration of corticosteroids. 12.Patients who have severe liver dysfunction (a high level of AST or ALT of at least 100 U / L). 13.Patients who have a history of allergies to the drugs intended for the study. 14. Patients with a malignant tumor or a history of malignant tumor. 15.Patients judged by the investigator as inappropriate as subjects.
研究者
相似试验
已完成
不适用
Evaluation of Preventive Effect of tofogliflozin on cardiovascular function in type 2 diabetes with cardiovascular diseasestype 2 diabetes with cardiovascular diseaseJPRN-UMIN000018344tofogliflozin study group30
未知
2 期
Clinical Pharmacology Study of Tofogliflozin --Evaluation of influence by degree of kidney functionType 2 diabetesJPRN-jRCT2080221532Chugai Pharmaceutical Co., Ltd.40
招募中
4 期
Effect of tofogliflozin on pancreatic beta-cell functioType 2 diabetesJPRN-jRCTs011230006akamura Akinobu70
未知
1 期
Clinical pharmacology study of Tofogliflozin in patients with hepatic impairmentType 2 diabetesJPRN-jRCT2080221650Chugai Pharmaceutical Co., Ltd.16
未知
1 期
Drug-drug interaction study (2) of TofoglifloziJPRN-jRCT2080221710Chugai Pharmaceutical Co., Ltd.87